New cocktail targets Hard-to-Treat myeloma

NCT ID NCT06042725

Recruiting now Disease control Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 21, 2026 · Updated 4 times

Summary

This early-stage trial is testing the safety of adding venetoclax to standard multiple myeloma treatments for people whose cancer cells have a specific genetic change called t(11;14). The study will enroll 100 participants and try different drug combinations to find the best doses. The goal is to see if these combinations can better control the cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Venetoclax (a Bcl-2 inhibitor) combined with lenalidomide, dexamethasone, and/or daratumumab
What this could lead to: If successful, this could offer a new, more effective treatment option for people with a specific genetic subtype of multiple myeloma (t(11;14)).
What could go wrong: This is an early Phase 1 trial focused on safety and dosing, so it is too soon to know if the combinations will work better than existing treatments. Side effects from the drug combinations are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Mayo Clinic in Rochester
RECRUITING

Rochester, Minnesota, 55905, United States

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.